8P - Male breast cancer: NEMROCK center experience

Date 04 May 2017
Event IMPAKT 2017
Session Welcome reception and Poster Walk
Topics Breast Cancer
Staging Procedures (clinical staging)
Basic Principles in the Management and Treatment (of cancer)
Presenter Soha Talima
Authors S.M. Talima, M. Eldaly
  • Clinical Oncology, NEMROCK, 0200 - Giza/EG




Male breast cancer is an infrequently presenting disease. Distribution of its molecular and prognostic parameters need some focusing.


A total of 36 cases of MBC were examined retrospectively using immunohistochemical analysis of estrogen receptor (ER), progesterone receptor (PR), Ki-67, and epidermal growth factor (Her2). Cases were classified as luminal A (ER+ and/or PR+, and HER2− and Ki67 low), luminal B (ER+ and/or PR+, and HER2+ or Ki67 high), HER2 (ER−, PR−, HER2+), triple-negative (negative for all markers).


The median age at presentation was 58 years. The predominant histology was invasive ductal carcinoma (97%). Most of the cases were presented with advanced disease (stage III, N=15, 41%), 6 patients have T size > 5cm, however more than 50 % got T4b disease, nodal involvement was N1= 11 patients, N2= 7, N3= 6 and 12 patients with inadequate axillary dissection. Seven patients presented with M1 disease.

Regarding IHC results, 75% were ER+VE and 68% were PR+VE. Three patients had tumors that were ER- and PR-negative. The distribution of molecular subtypes were 11 cases (30%) luminal A, 19 (52%) luminal B and 3 (8%) were triple negative. The Her2-+VE was identified in 3 (8%). The clinicpathological characteristics did not differ between luminal subtypes A and B. There were differences in median survival (34 vs. 19 month) between luminal A and B, however was not statistically significant (p = 0.77).

In a median FU of 3 years, 6 patients developed distant metastatic disease (two with simultaneous local recurrence). They were distributed as 2 patients luminal A, 2 luminal B, and 2 for HER2 and Triple negative.


The commonest subtypes in our cohort of MBC were luminal B followed by luminal A. There were some differences in median survival between luminal A and B subtypes, however was not statistically significant.

Clinical trial identification